We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+22.06%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.12B
AUM Growth
+$87.3M
Cap. Flow
-$105M
Cap. Flow %
-9.42%
Top 10 Hldgs %
48.85%
Holding
77
New
7
Increased
18
Reduced
19
Closed
8

Top Buys

Rank Stock Value
1
HRTX icon
Heron Therapeutics
HRTX
+$29.7M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$15.7M
3
TVTX icon
Travere Therapeutics
TVTX
+$15.4M
4
ACOR
Acorda Therapeutics
ACOR
+$15M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$13.1M

Top Sells

Rank Stock Value
1
RPTP
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
+$41.1M
2
NVRO
NEVRO CORP.
NVRO
+$30.9M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.6M
4
CSII
Cardiovascular Systems, Inc.
CSII
+$21.8M
5
ANGO icon
AngioDynamics
ANGO
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 84.53%
2 Financials 0.24%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACOR
26
DELISTED
Acorda Therapeutics
ACOR
$12.6M 1.13%
+5,039
New +$15M
DSCI
27
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$12M 1.07%
2,562,104
– –
SPNE
28
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$11.1M 1%
1,100,007
– –
QLTI
29
DELISTED
QLT Inc
QLTI
$10.9M 0.97%
5,269,831
+824,304
+19% +$1.23M
CORI
30
DELISTED
Corium International, Inc.
CORI
$10.8M 0.97%
1,919,721
– –
AMRN
31
Amarin Corp
AMRN
$285M
$10.7M 0.96%
167,952
-65,809
-28% -$3.69M
ELGX
32
DELISTED
Endologix Inc
ELGX
$10.2M 0.92%
80,000
-20,000
-20% -$2.56M
PRTK
33
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$10.2M 0.92%
786,134
-17,198
-2% -$228K
XENT
34
DELISTED
Intersect ENT, Inc
XENT
$10.1M 0.91%
638,600
-72,000
-10% -$1.08M
ZGNX
35
DELISTED
Zogenix, Inc.
ZGNX
$10.1M 0.9%
882,312
– –
RDHL
36
Redhill Biopharma
RDHL
$4.06M
$9.96M 0.89%
717
-20
-3% -$280K
MDCO
37
DELISTED
Medicines Co
MDCO
$9.65M 0.86%
255,600
– –
ASRT
38
DELISTED
Assertio
ASRT
$9.47M 0.85%
6,325
+914
+17% +$1.15M
CPRX
39
DELISTED
Catalyst Pharmaceutical
CPRX
$8.94M 0.8%
8,200,000
– –
DRRX
40
DELISTED
DURECT Corp
DRRX
$8.89M 0.8%
639,521
+349,521
+121% +$5.74M
SBBP
41
DELISTED
Strongbridge Biopharma plc.
SBBP
$8.65M 0.78%
1,656,706
– –
EGLT
42
DELISTED
Egalet Corporation
EGLT
$8.63M 0.77%
1,134,750
– –
ADMA icon
43
ADMA Biologics
ADMA
$1.94B
$8.06M 0.72%
1,113,293
– –
VXRT
44
DELISTED
Vaxart
VXRT
$6.69M 0.6%
316,974
– –
MRTX
45
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$6.61M 0.59%
1,000,000
+306,137
+44% +$1.63M
ACGN
46
DELISTED
Aceragen Inc
ACGN
$6.21M 0.56%
17,869
-4,909
-22% -$1.3M
RPTP
47
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$5.96M 0.53%
664,800
-5,785,200
-90% -$41.1M
SCYX icon
48
SCYNEXIS
SCYX
$39.3M
$5.72M 0.51%
18,466
– –
CSII
49
DELISTED
Cardiovascular Systems, Inc.
CSII
$5.47M 0.49%
230,532
-996,969
-81% -$21.8M
NVRO
50
DELISTED
NEVRO CORP.
NVRO
$5.28M 0.47%
50,555
-341,800
-87% -$30.9M
1
2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q3 2016 Portfolio in Review

As of Q3 2016, Broadfin Capital held 77 positions worth $1.12B, up 8.5% from $1.03B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Broadfin Capital withdrew a net $105M in Q3 2016, closing 8 positions and reducing 19 holdings. Its most notable exit was Genomic Health, Inc., an estimated $7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 73% a quarter earlier, followed by Financials and Technology.

Against the trend, Broadfin Capital opened a new position in Teva Pharmaceuticals worth $13.8M.

  • Broadfin Capital's largest Q3 2016 buy was Teva Pharmaceuticals: 300,000 shares worth $13.8M.
  • Broadfin Capital added most to Heron Therapeutics in Q3 2016, an estimated $29.7M increase.
  • Broadfin Capital's biggest Q3 2016 reduction was RAPTOR PHARMACEUTICAL CORP COM STK (DE), cutting an estimated $41.1M.
  • Broadfin Capital fully exited Genomic Health, Inc. in Q3 2016, selling an estimated $7M.
  • Broadfin Capital's ten largest holdings make up 49% of its $1.12B portfolio in Q3 2016.
  • Broadfin Capital opened 7 new positions and closed 8 in Q3 2016.
  • Broadfin Capital's portfolio value rose 8.5% quarter-over-quarter to $1.12B.

Based on Broadfin Capital's 13F filing for Q3 2016, filed 14 Nov 2016.